IMC Company Update on CDI Clinical Trial and New Strategic Focus 19/03/19 PRICE SENSITIVE Share IMC Half Yearly Report and Accounts 28/02/19 PRICE SENSITIVE Share IMC Travelan FY19 Update and Expansion into North America 29/01/19 PRICE SENSITIVE Share IMC Form F-3 15/01/19 PRICE SENSITIVE Share IMC Immuron Receives $1.19M R&D Tax Concession Refund 03/01/19 PRICE SENSITIVE Share IMC IMC Appoints Experienced US Based Biotech Executive as CEO 19/11/18 PRICE SENSITIVE Share IMC NASH clinical trial presentation & continued revenue growth 09/11/18 PRICE SENSITIVE Share IMC US DoD Report Travelan Protects Against Shigella in Primates 05/09/18 PRICE SENSITIVE Share IMC Preliminary Final Report 30/08/18 PRICE SENSITIVE Share IMC Immuron Reports Record Revenue 25/07/18 PRICE SENSITIVE download Created with Sketch. 872.69KB Share IMC US Department of Defense Research Collaboration Moves Ahead 16/07/18 PRICE SENSITIVE download Created with Sketch. 881.93KB Share IMC European Patent Gramted for Nash Treatment 11/07/18 PRICE SENSITIVE download Created with Sketch. 782.89KB Share IMC Immuron Announces Board Appointment 26/06/18 PRICE SENSITIVE download Created with Sketch. 815.87KB Share IMC Trading Halt 25/06/18 PRICE SENSITIVE download Created with Sketch. 221.37KB Share IMC IMC Preclinical Study Reports Reduction in Colitis Symptoms 08/05/18 PRICE SENSITIVE Share IMC Travelan Sales Continue to Soar in Third Quarter of FY2018 23/04/18 PRICE SENSITIVE Share IMC Immuron Announces A$5.1M Private Placement to U.S. Fund 14/03/18 PRICE SENSITIVE Share IMC Immuron Progresses Discussions with Institutional Funds 13/03/18 PRICE SENSITIVE Share IMC Trading Halt 12/03/18 PRICE SENSITIVE Share IMC Immuron Reports Positive Results in NASH Clinical Trial 08/03/18 PRICE SENSITIVE Share IMC Correction to False and Misleading News Release 07/03/18 PRICE SENSITIVE Share IMC Trading Halt 07/03/18 PRICE SENSITIVE Share IMC Appendix 4D - Half Year Financial Report - 31 Dec 2017 28/02/18 PRICE SENSITIVE Share IMC Travelan Revenue Grows Significantly in US and Australia 16/02/18 PRICE SENSITIVE Share IMC US Defence Depart Report-Travelan Targets Priority Pathogens 30/01/18 PRICE SENSITIVE Share IMC Immuron to Receive $2.16M R&D Tax Concession Cash Refund 23/01/18 PRICE SENSITIVE Share IMC Immuron Granted US Patent for NASH Treatment 14/11/17 PRICE SENSITIVE Share IMC Immuron Successfully Completes NASH Phase II Clinical Study 09/11/17 PRICE SENSITIVE Share IMC Travelan Experiences Strong Q1 FY2018 Sales Growth 08/11/17 PRICE SENSITIVE Share IMC Appendix 4E Preliminary Final Report (30 June 2017) 31/08/17 PRICE SENSITIVE Share IMC Immuron Opens Clinical Site to Commence C.Diff CDI Study 28/08/17 PRICE SENSITIVE Share IMC Immuron Approved to Commence Clinical Study in C.Difficile 09/08/17 PRICE SENSITIVE Share IMC Immuron to Present C.difficile Data at ClostPath 2017 Confer 08/08/17 PRICE SENSITIVE Share IMC Immuron Announces Management Changes 03/08/17 PRICE SENSITIVE Share IMC Success of NASH Phase II Interim Analysis Explained Further 13/07/17 PRICE SENSITIVE Share IMC NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes 10/07/17 PRICE SENSITIVE Share IMC Pre-Clinical C. difficile Infection Results Paper Published 03/07/17 PRICE SENSITIVE Share IMC IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M 09/06/17 PRICE SENSITIVE Share IMC Trading Halt 08/06/17 PRICE SENSITIVE Share IMC Travelan Increases Industry Presence - Conf & Sales Update 02/06/17 PRICE SENSITIVE Share IMC Immuron Secures $1.5M R&D Cash Advance Loan Funding 01/06/17 PRICE SENSITIVE Share IMC NASDAQ Listing on Hold Pending NASH Interim Analysis Results 01/06/17 PRICE SENSITIVE Share IMC Trading Halt 30/05/17 PRICE SENSITIVE Share IMC IMC Expands Agreement with US Army-3 Additional Therapeutics 16/05/17 PRICE SENSITIVE Share IMC Completion of Manufacturing of Drug Product for C-Diff Trial 10/05/17 PRICE SENSITIVE Share IMC IMC Form F1 - US Registration Statement (Prelim. Prospectus) 09/05/17 PRICE SENSITIVE Share IMC Positive Results of IMM-124E in Acute Colitis Studies 18/04/17 PRICE SENSITIVE Share IMC Close of Recruitment of Phase II NASH Trial 06/04/17 PRICE SENSITIVE Share IMC Appendix 4D - Half Year Report and Accounts - Dec 2016 28/02/17 PRICE SENSITIVE Share IMC Immuron Completes Phase II NASH Clinical Trial Recruitment 20/02/17 PRICE SENSITIVE Share IMC First Patient in Pediatric Fatty-Liver Phase II Trial 06/02/17 PRICE SENSITIVE Share IMC NASH MOA Study commences with SanyalBio & Duke University 19/01/17 PRICE SENSITIVE Share IMC Immuron Receives $1.6M R&D Tax Concession Refund 29/11/16 PRICE SENSITIVE Share IMC Immurons NASH Phase II Trial Achieves 100 Patient Milestone-IMC.AX 28/10/16 PRICE SENSITIVE Share IMC NASH Phase II Trial reaches 75% of Patient Recruitment-IMC.AX 10/10/16 PRICE SENSITIVE Share IMC Immurons $6M Rights Issue Closes Oversubscribed-IMC.AX 04/10/16 PRICE SENSITIVE Share IMC Appendix 4E and Annual Report-IMC.AX 30/08/16 PRICE SENSITIVE Share IMC Immuron Expands Collaborate with US Navy-IMC.AX 30/08/16 PRICE SENSITIVE Share IMC US NIH to Fund Second IMC Fatty Liver Study - Pediatric NASH-IMC.AX 18/08/16 PRICE SENSITIVE Share IMC Travelan to be Stocked by US Distributor Medique Products-IMC.AX 08/08/16 PRICE SENSITIVE Share IMC Immuron to Cooperate with Universities on Autism Research-IMC.AX 20/07/16 PRICE SENSITIVE Share IMC Immuron to repay outstanding Convertible Note in cash-IMC.AX 18/07/16 PRICE SENSITIVE Share IMC IMC Signs Shigella Vaccine Developmt Agreement with US Army-IMC.AX 21/06/16 PRICE SENSITIVE Share IMC Travelan and Protectyn Are Now Available For Sale in China-IMC.AX 16/06/16 PRICE SENSITIVE Share IMC Travelan to Reach Upto 1.5M New US Customers via Magellans-IMC.AX 14/06/16 PRICE SENSITIVE Share IMC Immuron Rights Issue Offer Booklet (May 2016)-IMC.AX 31/05/16 PRICE SENSITIVE Share IMC Immuron Announces $6M Rights Issue Offer-IMC.AX 31/05/16 PRICE SENSITIVE Share IMC Trading halt-IMC.AX 27/05/16 PRICE SENSITIVE Share IMC NASH Phase II Trial Reaches 50% Recruitment Milestone-IMC.AX 25/05/16 PRICE SENSITIVE Share IMC Immuron Announces E-Commerce Agreement with QBID in China-IMC.AX 09/05/16 PRICE SENSITIVE Share IMC US Distribution Reach Expanded through McKesson-IMC.AX 28/04/16 PRICE SENSITIVE Share IMC US Travelan Sales Network Widened by Allocation Inc Ptnrship-IMC.AX 19/04/16 PRICE SENSITIVE Share IMC Expansion of US Travelan Sales Following CVS Pharmacy Launch-IMC.AX 14/04/16 PRICE SENSITIVE Share IMC Appendix 4D - Half Yearly Report and Accounts 25/02/16 PRICE SENSITIVE Share IMC Immuron Initiates Pre-Clinical Colitis Development Program 22/02/16 PRICE SENSITIVE Share IMC Immuron Secures upto $1.7M Equity & Convertible Note Funding 17/02/16 PRICE SENSITIVE Share IMC Immuron Receives $1.47M R&D Tax Concession Refund 04/02/16 PRICE SENSITIVE Share IMC Analyst Reports on Immuron IMM-529 C. difficile Program 14/01/16 PRICE SENSITIVE Share IMC IMC Achieves Outstanding Results in C-Diff Recurrence Study 12/01/16 PRICE SENSITIVE Share IMC IMC Reports Highly Successful C-Diff Pre-Clinical Results 22/12/15 PRICE SENSITIVE Share IMC NASH Clinical Trial Surpasses 25% Patient Recruitment Level 18/11/15 PRICE SENSITIVE Share IMC IMC Signs US Travelan Sales Agreement with Medico-Mart Inc 12/11/15 PRICE SENSITIVE Share IMC NASH Diagnostic Collaboration Agreement - OWL Metabolomics 09/11/15 PRICE SENSITIVE Share IMC Passport Health - Sales Partnership Agreement 26/10/15 PRICE SENSITIVE Share IMC Appendix 4E Preliminary Final Report & Annual Report 28/08/15 PRICE SENSITIVE Share IMC Immuron Appoints New Chief Executive Officer 25/08/15 PRICE SENSITIVE Share IMC Proposed Issue of Unlisted Options 06/08/15 PRICE SENSITIVE Share IMC Immuron Executes Major US Travelan Sales Agreement 04/08/15 PRICE SENSITIVE Share IMC Resignation of Chief Executive Officer 08/07/15 PRICE SENSITIVE Share IMC NASH Clinical Trial Update - Patient Recruitment Advances 02/07/15 PRICE SENSITIVE Share IMC IMMURON ANNOUNCES FIRST USA ORDERS FOR TRAVELAN 20/04/15 PRICE SENSITIVE Share IMC Immuron Appoints Dr. Leearne Hinch as New CEO 02/04/15 PRICE SENSITIVE Share IMC Appendix 4D - Half Yearly Report and Accounts 18/02/15 PRICE SENSITIVE Share IMC Marketing and Distribution Agreement signed for China 17/02/15 PRICE SENSITIVE Share IMC Patient Recruitment Commenced for Phase 2 NASH Trial 03/02/15 PRICE SENSITIVE Share IMC IMC signs License Agreement for Development for Alcohol Tox 06/01/15 PRICE SENSITIVE Share IMC Resignation of CEO 18/12/14 PRICE SENSITIVE Share IMC Immuron Completes Capital Consolidation 20/11/14 PRICE SENSITIVE Share IMC NASH & ASH Clinical Trial Update 15/10/14 PRICE SENSITIVE Share IMC Immuron Improves Hadasit Royalty Terms 02/09/14 PRICE SENSITIVE Share
